ALX-804-665-C100

antibody from Enzo Life Sciences

Targeting: TNFRSF10A Apo2, CD261, DR4, TRAILR-1, TRAILR1

Western blot (Recommended by provider)

Immunohistochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Antibody Data

Product number

ALX-804-665-C100

Provider

Enzo Life Sciences

Product name

TRAIL-R1 (human) monoclonal antibody (TR1.02)

Antibody type

Monoclonal

Antigen

Recombinant full length protein

Description

Protein G-affinity purified.

Reactivity

Human

Host

Mouse

Isotype

IgG

Antibody clone number

TR1.02

Vial size

100 μg

Storage

-20°C

Handling

Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20¡C.

References

Submitted references

Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer.

Ganten TM, Sykora J, Koschny R, Batke E, Aulmann S, Mansmann U, Stremmel W, Sinn HP, Walczak H
Journal of molecular medicine (Berlin, Germany) 2009 Oct;87(10):995-1007

---

TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window.

Koschny R, Ganten TM, Sykora J, Haas TL, Sprick MR, Kolb A, Stremmel W, Walczak H
Hepatology (Baltimore, Md.) 2007 Mar;45(3):649-58

---

Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs.

Ganten TM, Koschny R, Sykora J, Schulze-Bergkamen H, Büchler P, Haas TL, Schader MB, Untergasser A, Stremmel W, Walczak H
Clinical cancer research : an official journal of the American Association for Cancer Research 2006 Apr 15;12(8):2640-6